Unum Therapeutics Inc. (UMRX) News
Filter UMRX News Items
UMRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest UMRX News From Around the Web
Below are the latest news stories about Unum Therapeutics Inc that investors may wish to consider to help them evaluate UMRX as an investment opportunity.
Venrock Healthcare Capital Partners acquires 0.451M shares of Unum TherapeuticsVenrock Healthcare Capital Partners discloses the purchase 0.451M shares of Unum Therapeutics (UMRX) between Aug. 14 and Aug. 18 at average price of $2.52/share.Shares +9% premarket.... |
Unum Therapeutics reports Q2 resultsUnum Therapeutics (UMRX): Q2 GAAP EPS of -$0.24.Revenue of $0.53M (-83.1% Y/Y)Shares -2.8% AH.Press Release... |
Kaskela Law LLC Announces Investigation of Unum Therapeutics Inc. and Encourages Long-Term Investors to Contact the Firm - UMRXKaskela Law LLC announces that it is investigating Unum Therapeutics Inc. (NASDAQ: UMRX) ("Unum" or the "Company") on behalf of the Company's investors. |
Top Ranked Momentum Stocks to Buy for July 17thTop Ranked Momentum Stocks to Buy for July 17th |
Unum Therapeutics rallies on disclosure of Fairmont stakeNano cap Unum Therapeutics (UMRX) jumps 18% premarket on robust volume on the heels of a disclosure from Fairmont Funds Management, LLC of a 19.99% stake consisting of ~6.4M common shares and ~1.3M common shares issuable upon the conversion of Series A non-voting convertible preferred stock.Earlier this week, Unum completed its acquisition... |
Unum Therapeutics Inc. (UMRX) Shares March Higher, Can It Continue?As of late, it has definitely been a great time to be an investor in Unum Therapeutics Inc. (UMRX). |
Unum Therapeutics (UMRX) Catches Eye: Stock Jumps 8.6%Unum Therapeutics (UMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes. |
Unum Therapeutics completes Kiq buy, inks $104M capital raiseUnum Therapeutics ([[UMRX]] +271.0%) has completed its acquisition of privately held Kiq, a developer of precision kinase inhibitors, in an all-stock deal.Concurrently, Unum has inked agreements with institutional investors for the sale of Series A Preferred Stock at $880 per share yielding gross proceeds of $104.4M. Each Series A share may... |
Unum Therapeutics Inc. Announces Acquisition of Kiq LLCUnum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biopharmaceutical company focused on developing therapies for solid tumors, today announced it has completed the acquisition of Kiq LLC ("Kiq"), a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors. Concurrent with the acquisition of Kiq, Unum entered into a definitive agreement for the sale of Series A non-voting convertible Preferred Stock (the "Series A Preferred Stock") in a private placement to a group of institutional accredited investors led by Fairmount Funds Management LLC ("Fairmount Funds"), with participation from Venrock Healthcare Capital Partners, BVF Partners L.P., Atlas Venture, Acorn Bioventures, Perceptive Advisor's L... |
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Unum Therapeutics Inc. for Potential Breach of Fiduciary Duty ClaimsNEW YORK, June 15, 2020 -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Unum Therapeutics Inc.. |